These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24701705)

  • 1. Baseline PSA testing for men in their 40s: currently available evidence strongly supports baseline PSA measurements in this age group.
    Catalona WJ
    Oncology (Williston Park); 2014 Feb; 28(2):154, 156. PubMed ID: 24701705
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed.
    Carter HB
    Oncology (Williston Park); 2014 Feb; 28(2):155-6. PubMed ID: 24701706
    [No Abstract]   [Full Text] [Related]  

  • 3. US guideline may have led to drop in PSA testing among primary care physicians, studies find.
    McCarthy M
    BMJ; 2015 May; 350():h2906. PubMed ID: 26021822
    [No Abstract]   [Full Text] [Related]  

  • 4. First, do no harm.
    Pimlott N
    Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
    Shahangian S; Sharma KP; Fan L; Siegel DA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
    Shahangian S; Fan L; Sharma KP; Siegel DA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1352. PubMed ID: 33932150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the use of prostate-specific antigen as an instrument for early detection of prostate cancer beyond urologists: results of a representative cross-sectional questionnaire study of general practitioners and internal specialists.
    Gilfrich C; May M; Braun KP; Lebentrau S; Lehsnau M; Ecke T; Schmailzl KJ; Al-Dumaini S; Hallmann S; Ahmed AM; Maurer J; Karl T; Braun V; Haferkamp A; Brookman-May S; Bauer RM; Stief CG; Hoschke B; Maurer O; Wolff I
    Urol Int; 2014; 93(2):160-9. PubMed ID: 24603136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance.
    Smith SD; Birtwhistle R
    Can Fam Physician; 2012 Sep; 58(9):e502-7. PubMed ID: 22972741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
    Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
    Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
    Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
    World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
    McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
    Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.
    Carey M; Bryant J; Yoong SL; Russell G; Barker D; Sanson-Fisher R
    BMC Fam Pract; 2013 Dec; 14():186. PubMed ID: 24321004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.
    Walsh EI; Turner EL; Lane JA; Donovan JL; Neal DE; Hamdy FC; Martin RM; ; ; ; ; ; ;
    Trials; 2016 Oct; 17(1):497. PubMed ID: 27737692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations.
    Rahbar H; Karabon P; Menon M; Trinh QD; Abdollah F
    Eur Urol Focus; 2018 Dec; 4(6):1002-1004. PubMed ID: 28753856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.